TUCSON, Ariz., Feb. 07, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced that management will present in a fireside chat at the LEERINK Partners 7th Annual Global Healthcare Conference, being held February 14-15 in New York City.
||Thursday, February 15
||2:00pm Eastern Time
||The Lotte New York Palace Hotel, Henry Room
Headquartered in Tucson, Arizona, the mission of HTG is to empower precision medicine at the local level. The company’s HTG EdgeSeq technology, which automates highly multiplexed molecular profiling of small samples for next-generation sequencing, received its first US patent in 2014. Continuous improvements led to the 2017 launch of HTG’s new direct-target sequencing chemistry for DNA analysis offered in the company’s VERI/O services laboratory.
LifeSci Advisors, LLC
HTG Molecular Diagnostics
Source: HTG Molecular Diagnostics, Inc.